Rigel Pharmaceuticals (RIGL)
(Delayed Data from NSDQ)
$15.08 USD
+0.58 (4.00%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $15.07 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.08 USD
+0.58 (4.00%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $15.07 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Zacks News
Company News for Apr 14, 2021
by Zacks Equity Research
Companies in the news are: MFNC, NVCR, RIGL, VTVT
Rigel Pharmaceuticals (RIGL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of -10.00% and 0.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Rigel Pharmaceuticals (RIGL) Stock?
by Zacks Equity Research
Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.
Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 33.33% and 4.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Rigel Announces Sponsored Mid-Stage Coronavirus Therapy Study
by Zacks Equity Research
Rigel Pharmaceuticals (RIGL) is developing its thrombocytopenia drug, Tavalisse, as a potential treatment for hospitalized COVID-19 patients.
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 23.08% and 12.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Rigel Pharmaceuticals (RIGL) Q2 Earnings Expected to Decline
by Zacks Equity Research
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: GILD, MRNA Give Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Rigel Pharmaceuticals (RIGL) Looks Good: Stock Adds 9.7% in Session
by Zacks Equity Research
Rigel Pharmaceuticals (RIGL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Aclaris Gets FDA Nod to Start Investigator-led Coronavirus Study
by Zacks Equity Research
Aclaris (ACRS) announces that it supports an IND application to evaluate its oral investigational MK2 inhibitor compound, ATI-450, in hospitalized patients with COVID-19.
Rigel Pharmaceuticals (RIGL) Q1 Earnings Match Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 0.00% and -2.08%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rigel Pharmaceuticals (RIGL) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 9.09% and -2.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I
by Zacks Equity Research
Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.
Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study
by Zacks Equity Research
Tyme (TYME) is evaluating its lead cancer candidate, SM-88, as third-line treatment for metastatic pancreatic cancer in a pivotal study.
Rigel Gets Positive CHMP Review for Thrombocytopenia Drug
by Zacks Equity Research
The CHMP advocates Rigel's (RIGL) marketing approval for Tavalisse to treat chronic immune thrombocytopenia in Europe.
Pharma Sector Tops in October: Best ETFs & Stocks
by Sanghamitra Saha
Pharma sector wins in October, making these ETFs and stocks winners.
Rigel Pharmaceuticals (RIGL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 36.36% and 28.19%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Rigel (RIGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris Divests Rhofade to EPI Health for $55M, Shares Up
by Zacks Equity Research
Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 14.29% and 12.56%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Bausch Health (BHC) in Q2 Earnings?
by Zacks Equity Research
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.
Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2019 results.
Rigel Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Rigel Pharmaceuticals, Inc. (RIGL) has been struggling lately, but the selling pressure may be coming to an end soon.